Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, LevitasBio is raising $35,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Pieprzyk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About LevitasBio
LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular processing and characterization. Our disruptive levitation technology overcomes current technological limitations by providing a gentle, simple and label-free method of isolating specific cell populations. The LeviCell platform enables studies and beneficial uses of previously inaccessible, high-value primary samples and sensitive cell types, regardless of the starting cell number, viability, or sensitivity to processing.

To learn more about LevitasBio, visit http://levitasbio.com/

Contact:
Martin Pieprzyk, Chief Executive Officer
415-947-2470
https://www.linkedin.com/in/martinpieprzyk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved